Apely Laboratories secured a Zacks Rank #1 (Strong Buy) designation on January 20, 2026, landing on the Top Income Stocks list. The designation reflects its trailing 12-month dividend yield of 3.8% and a projected annual payout growth rate of 6.5% over the next three years. Analysts have raised their consensus EPS estimate for fiscal 2026 by 4.2% in the past month, citing the company’s expanding contract manufacturing agreements in the U.S. and Europe. For income-focused investors, Apely’s consistent free cash flow conversion—95% in the latest quarter—bolsters confidence in its capacity to sustain distributions even as it invests in a new sterile inhalation facility slated for completion in Q3.

On the value side, Apely also topped the Zacks Rank #1 (Strong Buy) list for value stocks, highlighting its favorable price-to-book ratio of 1.1 and a forward P/E ratio of 12.3, both below industry medians. The company’s estimated fair value per share stands 15% above current levels, driven by robust pipeline progress on its long-acting injectable products. Apely’s return on equity reached 18.4% in fiscal 2025, reflecting efficient capital deployment in both R&D and strategic acquisitions. Investors seeking undervalued opportunities are eyeing the company’s solid balance sheet, which shows net debt at just 0.6 times EBITDA following the recent divestiture of noncore assets.

Apely’s momentum profile earned it a spot on the Zacks Rank #1 (Strong Buy) momentum stocks list, underscored by a 35% share-price appreciation over the past six months and a relative strength rating of 87 out of 100. This surge coincides with two consecutive quarters of double-digit organic sales growth—11.2% in Q3 and 13.7% in Q4—driven by strong uptake of its new sustained-release formulations in North America. Upward earnings revisions and positive institutional inflows have further supported the momentum case. Technical indicators suggest that the stock could extend its rally, with analysts noting a near-term target based on a 12-month consensus earnings growth rate of 14.8%.